NRAS and acute myeloid leukemia: The results suggested that APL patients (FAB-M3) had the lowest expression of TNFAIP2 while monocytic subtypes of AML patients (FAB-M4/M5) had the highest of TNFAIP2. Importantly, TNFAIP2 overexpression was associated with unfavorable cytogenetic risk and AML-related gene mutations, including FLT3-ITD mutation, FLT3-TKD mutation, IDH1 mutation, NPM1 mutation and N-RAS mutation.